Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 2/20 | 0.38 |
| ▸ | TSPO | P30536 | 2/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6214728 | 0.94 | FPR3 (0.37) | FPR3TSPOCRHR1TMEM97 | |
| SCHEMBL1636385 | 0.93 | CRHR1 (0.43) | FPR3TSPOCRHR1TMEM97 | |
| SCHEMBL6217815 | 0.91 | FPR3 (0.35) | FPR3TSPOCRHR1TMEM97 | |
| SCHEMBL6216295 | 0.86 | CRHR1 (0.37) | FPR3TSPOCRHR1TMEM97 | |
| SCHEMBL6217720 | 0.86 | FPR3 (0.33) | FPR3TSPOCRHR1TMEM97 | |
| SCHEMBL6217402 | 0.82 | CRHR1 (0.31) | FPR3TSPOCRHR1TMEM97 | |
| SCHEMBL6773652 | 0.81 | CRHR1 (0.53) | FPR3TSPOCRHR1TMEM97 | |
| SCHEMBL6214712 | 0.81 | GABRB3 (0.35) | FPR3TSPOCRHR1TMEM97 | |
| SCHEMBL14277045 | 0.79 | CRHR1 (0.43) | FPR3TSPOCRHR1TMEM97 | |
| SCHEMBL6220711 | 0.78 | CRHR1 (0.35) | FPR3TSPOCRHR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1176146-B1 | CARBAMOYL TETRAHYDROPYRIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-06-08 | — | — | EP | disclosed |
| US-6894168-B2 | Carbamoyl tetrahydropyridine derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-17 | — | — | US | disclosed |
| EP-1449843-A1 | Intermediates for the preparation of carbamoyl tetrahydropyridine derivatives | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-08-25 | — | — | EP | disclosed |
| US-20030191122-A1 | Carbamoyl tetrahydropyridine derivatives | NAKAZATO ATSURO (JP) | 2003-10-09 | — | — | US | disclosed |
| US-6600038-B1 | Intermediates for the preparation thereof are provided. The derivatives described above are effective for diseases which are believed to involve CRF. involving Corticotropin Releasing Factor (CRF), such as depression, anxiety, | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-29 | — | — | US | disclosed |
| EP-1176146-A1 | CARBAMOYL TETRAHYDROPYRIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191122-A1 | Carbamoyl tetrahydropyridine derivatives | CNR1, CRHR1, CRH | FPR3 139/4885TSPO 2199/4885CRHR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.